Concept: Clinical endpoint
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial
IDH1 inhibitor shows disease control in hard-to-treat cartilage tumors
FMT with immunotherapy showed activity in NSCLC and melanoma
Gut bacteria transplants enhance immune cancer therapy effectiveness in lung and skin cancers
Image Credit: Image source: Stock provider
